GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performa...

Full description

Bibliographic Details
Main Authors: Paola Sette, Nduka Amankulor, Aofei Li, Marco Marzulli, Daniela Leronni, Mingdi Zhang, William F. Goins, Balveen Kaur, Chelsea Bolyard, Timothy P. Cripe, Jianhua Yu, E. Antonio Chiocca, Joseph C. Glorioso, Paola Grandi
Format: Article
Language:English
Published: Elsevier 2019-12-01
Series:Molecular Therapy: Oncolytics
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770519300956

Internet

http://www.sciencedirect.com/science/article/pii/S2372770519300956

Similar Items